MW: 817.9 g/mol (also known as Pralmorelin or Growth HormoneReleasing Peptide2) Key Benefits Research and Clinical Studies - Growth Hormone & Hormonal Modulation: Clinical trials in GHdeficient subjects indicate that the CJC1295, Ipamorelin markedly elevates GH secretion via dual activation of the pituitary and hypothalamic pathways
Call/Text our clinic at (801) 318-4260 to discuss if CJC-1295+Ipamorelin Peptides align with your therapy goals.
However, the extent of this association is unclear since some studies have reported a 7.6-fold increase in the rate of colorectal cancers in acromegalic patients compared with control groups (275), whereas another study has reported as low as twofold increased risk of colorectal cancer in acromegalic patients (286, 287)
On testing cadence, note that there is no universal evidence-based schedule: the frequency of laboratory monitoring should be individualized according to the therapy being used, underlying medical conditions, treatment response, and current clinical guidelines
If your provider recommends a stack, ask them to walk you through the rationale and any additional monitoring required
As tacrolimus has a narrow therapeutic window, frequent monitoring of whole blood concentrations in early postoperative settings is essential to optimize dosing
